PN-943

Is PN-943 safe?

Press release data; 12 weeks only

In the phase 2 trial, adverse events were described as balanced between PN-943 and placebo. The sponsor's summary reported no serious safety signal. The peptide is barely absorbed. So side effects in the body were expected to be few. Only 159 patients were treated, for 12 weeks. The full trial has no peer-reviewed publication. So the safety picture is thin. It rests on a press release and a conference presentation. ²

Read the full PN-943 page

Reference information only, not medical advice. Drawn from the PN-943 article, fact-checked against the cited sources. No dosing anywhere on this site.